Developer docs
API playgroundTry for free, no card

Search company profiles

TempraMed

Full company profile

uuid0000ifb

Namestring
TempraMed
Legal namestring
TempraMed Inc.
Websiteurl
tempramed.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

TempraMed Inc. designs, manufactures, and sells a portfolio of temperature-regulated medication storage devices under the VIVI brand for patients using injectable medications. The company's core product, VIVI Cap, is a thermal insulin pen carrying case using patented space-grade insulation combined with Phase Change Material (PCM) heat absorption that passively maintains insulin and GLP-1 medications within safe temperature (36–86°F) without batteries, water, ice, or charging. The portfolio extends to VIVI Epi (epinephrine auto-injector shield), VIVI Med (vial/ biologic case), and the recently launched VIVI Cap Smart (Bluetooth-connected version with mobile app, injection tracking, dose reminders, and shareable reports for healthcare providers). The flagship technology is supported by 9 global patents (notably granted in China in March 2026 and Brazil in April 2026 covering VIVI Box through 2039), FDA and CE registration, and a peer-reviewed clinical study published in Expert Opinion on Drug Delivery demonstrating an 86% time-in-range glycemic outcome vs. 82% without thermal protection.

TempraMed monetizes primarily through one-time hardware sales at an MSRP of $168/unit, with a B2B pharmacy starter pack pricing of $75/unit per 5-unit bundle and a subscription/annual membership pricing (~30% savings vs. monthly) introduced with VIVI Cap Smart. Distribution combines direct-to-consumer e-commerce (tempramed.com with HSA/FSA support), major US retail and pharmacy channels (CVS, Walmart, Walgreens, Amazon, McKesson, Humana, US Department of Veteran Affairs), large healthcare systems in Israel (Super-Pharm, Maccabi Healthcare Services covering 2.8 million insured members), and seven international distribution agreements covering Turkey, Benelux, South Korea, Panama, Saudi Arabia, and Brazil. Go-to-market also includes a physician engagement platform (FrontrowMD with 275+ recommending clinicians) and a strategic media partnership with Dr. Phil's Envoy Media providing access to ~19M monthly viewers.

The company operates as a publicly traded entity on the Canadian Securities Exchange under the symbol VIVI (IPO October 2025) and Frankfurt Stock Exchange (November 2025), with primary entity TempraMed Ltd. (Israel) and US operations headquartered in Sammamish, Washington, plus a Texas distribution warehouse and a Florida manufacturing facility opened in December 2025 with ~1M units/year capacity. Leadership includes Founder/CEO Ron Nagar (serial medical device entrepreneur and former InsuLine Medical and Glucon co-founder), Co-Founder/COO Elina Nagar, Executive Chairman Ilan Cohen, CFO Gabi Kabazo, and CFO Israel Shay Levin, supported by a Scientific Advisory Board featuring diabetes research luminaries including Prof. Dr. Lutz Heinemann. Approximately 100,000+ units have been sold to date with a ~30% repeat purchase rate, against a stated addressable market of 160 million patients and $30 billion in global opportunity; 2024 revenue was US$2.2M with management projecting ~US$15M for 2026.

Short descriptiontext

TempraMed designs and sells FDA/CE-registered VIVI thermal-protection cases for insulin and GLP-1 pens, epinephrine auto-injectors, vials, and biologics, using patented space-grade insulation and Phase Change Material technology for patients managing diabetes, severe allergies, and specialty medication regimens globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSammamish, United States
HQ citystring
Sammamish
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
insulin pen protection, temperature-controlled medication storage, cold chain medical devices, GLP-1 pen cases, EpiPen temperature shield
Industry1 code
PRIMARYCRADAMAK
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Temperature-Controlled Medical Storage Devices
No data
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model5 records
1Hardware Sales - VIVI Cap
TypeHardware Sales
Description

One-time sale of VIVI Cap thermal insulin pen protection device; reusable for years, priced at $168/unit MSRP for B2B/pharmacy

tempramed.com
2Hardware Sales - VIVI Epi
TypeHardware Sales
Description

One-time sale of VIVI Epi EpiPen temperature shield for epinephrine auto-injectors

tempramed.com
3Hardware Sales - VIVI Med
TypeHardware Sales
Description

One-time sale of VIVI Med medication temperature protection case for vials and injectable medications including biologics and GLP-1s

tempramed.com
4Hardware + Subscription - VIVI Cap Smart
TypeSubscription Recurring
Description

Connected device combining thermal protection with digital tracking; introduces subscription-based revenue model alongside hardware sales for app features and data reports

finance.yahoo.com
5Recurring Revenue from Repeat Purchases
TypeSubscription Recurring
Description

~30% of customers make repeat purchases; loyalty program with points-based rewards

tempramed.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels11 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure
Pricing details3 tiers
1B2B Pharmacy Starter Pack
ModelUnit PricingBilling cadencePay-as-you-go
Notes

5 units at $75/unit ($15/unit) for pharmacy starter orders; MSRP $168/unit for individual units

tempramed.com
2VIVI Cap Smart Subscription
ModelSubscriptionBilling cadenceAnnual
Notes

Yearly membership option offering 30% savings compared to monthly; includes app features, PDF reports, trends analysis

tempramed.com
3Consumer Direct - Multi-Unit Bundle
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Limited time promotional offers (40% off on 2+ units); bundle and save pricing; accepts HSA/FSA payments

tempramed.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1VIVI Cap Smart
Description

Digitally connected temperature protection device for insulin and GLP-1 pens with injection tracking and mobile app connectivity

tempramed.com
+5 more records
Core offering1 text field

TempraMed designs, manufactures, and sells the VIVI line of medical-device carrying cases that passively maintain injectable medications within their safe temperature range (36–86°F) using patented space-grade insulation and self-regenerating Phase Change Material. The portfolio includes VIVI Cap and VIVI Cap Smart (insulin/GLP-1 pen cases), VIVI Epi (epinephrine auto-injector shield), and VIVI Med (vial and biologic case), with the connected VIVI Cap Smart adding Bluetooth injection tracking via a mobile app.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 86% time-in-range vs 82% without thermal protection (clinical study in Greece)
+4 more records
Product overview1 text field

TempraMed offers a portfolio of temperature-regulated medication storage products under the VIVI brand. The core offerings include VIVI Cap (insulin pen protection), VIVI Cap Smart (digital version with tracking), VIVI Epi (EpiPen protection), and VIVI Med (vial/biologic protection). The products use patented space-grade thermal insulation technology with phase change material for passive temperature control. VIVI Cap Smart adds digital health features including Bluetooth connectivity, injection tracking, and mobile app integration. Upcoming products include VIVI Box (multi-medication platform) and VIVI Cool 8C (drug storage). All products are FDA and CE registered, manufactured in the USA, and designed for the 'last mile' of medication temperature control from pharmacy to patient use.

Product and service5 records
1VIVI Cap
CategoryInsulin pen protection
Description

Thermal insulin pen carrying case that protects insulin and GLP-1 pens from extreme temperatures using patented space-grade insulation and phase change material; maintenance-free, no batteries, works 24/7/365.

2VIVI Cap Smart
CategoryConnected insulin pen protection
Description

Advanced digital version of VIVI Cap combining space-grade thermal protection with injection-time tracking, Bluetooth connectivity, and a mobile application for dose logging, reminders, and shareable PDF/CSV health-provider reports.

3VIVI Epi
CategoryEpinephrine auto-injector protection
Description

EpiPen temperature shield that protects epinephrine auto-injectors from extreme temperatures and light to ensure efficacy during anaphylaxis; FDA- and CE-registered, maintenance-free.

4VIVI Med
CategoryVial and biologic protection
Description

Temperature protection case for vials and injectable medications including biologics, GLP-1s, Humira, and blood glucose test strips; holds up to 2 vials and is reusable for years.

5VIVI Box
CategoryMulti-medication storage
Description

Upcoming multi-medication storage platform with thermal insulation and smart-monitoring architecture for continuous temperature protection, portable travel functionality, and cloud-based content tracking across Brazil, China, and other markets.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Rawafed Health International Company
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-26
Description

Non-binding LOI for 5-year exclusive distribution arrangement in Saudi Arabia with minimum purchase orders of approximately US$3.1 million. Exclusivity contingent upon Saudi FDA regulatory approval and first commercial order of at least US$170,000. Initial product coverage is VIVI Cap targeting Saudi Arabia's 5.34 million adults with diabetes.

newsfilecorp.com
2TEM Consulting International S.A.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-30
Description

Non-binding LOI for distribution of VIVI temperature-regulated medication storage products across Panama. Definitive agreement expected within 90 days. Partnership targets Panama's growing diabetes and obesity markets with initial focus on urban, higher-income private-pay patients.

newsfilecorp.com
Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2026-02-26
Description

Physician engagement platform partnership launched December 2025 where over 275 physicians across the United States recommend VIVI Cap to patients. Positions product within clinical workflow to drive patient adoption beyond traditional pharmacy channels.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-10
Description

National rollout of TempraMed's temperature-protection medication products across Super-Pharm, Israel's largest pharmacy chain. Gives TempraMed access to millions of consumers through one of Israel's most trusted healthcare platforms. Products available across Super-Pharm's nationwide locations including VIVI Cap and VIVI Epi.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-06
Description

National brick-and-mortar and online pharmacy rollout through Maccabi Healthcare Services, Israel's second-largest HMO serving over 2.8 million insured members. First in-store and online sales milestone demonstrating scale execution within large healthcare system.

Strategic tierFlagshipTypeGTM or Marketing PartnerAnnounced on2026-02-02
Description

Strategic media partnership securing exclusive title sponsorship of 44-minute television special on prescription medication safety airing May 2026. Provides access to approximately 19 million monthly viewers across broadcast TV, podcasts, YouTube, and social media platforms. TempraMed receives full content usage rights for digital acquisition, enterprise sales, and international expansion.

7Mavens Co. Ltd
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-02
Description

Expanded distribution partnership with Mavericks Co. Ltd (Mavens) in South Korea supporting growth across Asia. Partnership strengthens TempraMed's footprint in South Korea's healthcare ecosystem targeting pharmacies, hospitals, and clinics. South Korean diabetes medications sector valued at nearly US$1 billion.

biospace.com
8Professor Dr. Lutz Heinemann
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-10
Description

Appointment to Scientific Advisory Board. Renowned diabetes researcher providing expertise in diabetes and medication stability science to support TempraMed's thermal-stability technology expansion.

newsfilecorp.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-05
Description

Distribution partnership expanding into Western Europe covering Benelux region (Netherlands, Belgium, and Luxembourg). Aims to increase access to TempraMed's temperature-sensitive medication storage products amid rising diabetes prevalence.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-02
Description

Exclusive distribution agreement to market and sell VIVI line of medication temperature-stabilizing products in Turkey. Capitalizes on Turkey's high diabetes prevalence where about 10 million people have diabetes.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-26
Description

Exclusive distribution agreement with leading consumer health distributor in Israel. Supports TempraMed's shift from online direct-to-consumer sales towards large retail pharmacy networks and medical payers globally.

12bullVestor Medien GmbH
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-11-18
Description

Marketing services agreement associated with Frankfurt Stock Exchange listing. Involves fee of approximately €130,000 for investor awareness services.

newsfilecorp.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-10-27
Description

In-kind partnership supporting 55 runners, many living with diabetes, at the 2025 TCS New York City Marathon. Provides temperature-protective solutions for runners' medications during the race.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Frio UK
TypeDirect peer
Description

Frio UK makes evaporative cooling wallets and pouches specifically designed to keep insulin and other temperature-sensitive medications cool without refrigeration. They are a direct competitor to TempraMed's VIVI Cap, addressing the same 'last mile' cold-chain problem for insulin users via a different cooling mechanism (evaporation vs. PCM).

24AllFamily
TypeDirect peer
Description

4AllFamily produces insulated medication travel cases and cooling pouches for insulin, GLP-1 medications, and biologics, directly overlapping with TempraMed's VIVI Cap and VIVI Med products. They compete for the same insulin/GLP-1 patient demographic with a similar DTC e-commerce model.

3Medicool
TypeDirect peer
Description

Medicool manufactures insulin protector cases and cooling wallets for diabetes patients, including products designed for portable temperature control of insulin pens and vials. They are a legacy direct competitor in the insulin storage category that TempraMed is disrupting with newer PCM-based technology.

TypeBroad incumbent
Description

Becton Dickinson is a global medical technology giant with a broad portfolio of drug delivery devices (including insulin pens, auto-injectors, and prefilled syringes) and medication management accessories. While not focused on temperature protection specifically, BD has the scale and distribution to enter TempraMed's niche.

TypeEmerging player
Description

Apex Medical develops medical device accessories for chronic disease management, with overlap in medication storage and portability products. While broader in scope, they are an emerging player in adjacent patient-focused medical device categories.

TypeOthers
Description

The world's largest insulin manufacturer and major GLP-1 producer (Ozempic, Wegovy). While not a direct competitor, Novo Nordisk could choose to bundle or co-promote temperature protection accessories with their injectable medications, representing both a potential partner and a threat to TempraMed's market position.

TypeOthers
Description

Major GLP-1 manufacturer (Mounjaro, Zepbound) and insulin producer. As with Novo Nordisk, Lilly represents both a potential partner opportunity and a competitive threat, as they could develop proprietary or branded temperature protection solutions for their injectable portfolio.

TypeEmerging player
Description

Swiss-based manufacturer of insulin pens, auto-injectors, and smart injection devices. Their mySmartPilot and YpsoMate platforms overlap with TempraMed's VIVI Cap Smart in addressing smart injection tracking for diabetes patients, though Ypsomed focuses on delivery rather than temperature protection.

TypeOthers
Description

Insulet manufactures the Omnipod insulin patch pump, a leading insulin delivery system. While not directly competing in temperature protection, Insulet targets the same diabetes patient demographic and represents an adjacent diabetes management technology competitor.

TypeBroad incumbent
Description

Global medical device leader with diabetes (insulin pumps, CGM) and broader medical device portfolios. Susan Alpert, former Senior VP Global Regulatory Affairs at Medtronic, sits on TempraMed's advisory board, highlighting the potential incumbent threat in medication management devices.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TempraMed

Temperature-Controlled Medical Storage Devicestempramed.com

TempraMed designs and sells FDA/CE-registered VIVI thermal-protection cases for insulin and GLP-1 pens, epinephrine auto-injectors, vials, and biologics, using patented space-grade insulation and Phase Change Material technology for patients managing diabetes, severe allergies, and specialty medication regimens globally.

What TempraMed does

TempraMed Inc. designs, manufactures, and sells a portfolio of temperature-regulated medication storage devices under the VIVI brand for patients using injectable medications. The company's core product, VIVI Cap, is a thermal insulin pen carrying case using patented space-grade insulation combined with Phase Change Material (PCM) heat absorption that passively maintains insulin and GLP-1 medications within safe temperature (36–86°F) without batteries, water, ice, or charging. The portfolio extends to VIVI Epi (epinephrine auto-injector shield), VIVI Med (vial/ biologic case), and the recently launched VIVI Cap Smart (Bluetooth-connected version with mobile app, injection tracking, dose reminders, and shareable reports for healthcare providers). The flagship technology is supported by 9 global patents (notably granted in China in March 2026 and Brazil in April 2026 covering VIVI Box through 2039), FDA and CE registration, and a peer-reviewed clinical study published in Expert Opinion on Drug Delivery demonstrating an 86% time-in-range glycemic outcome vs. 82% without thermal protection.

TempraMed monetizes primarily through one-time hardware sales at an MSRP of $168/unit, with a B2B pharmacy starter pack pricing of $75/unit per 5-unit bundle and a subscription/annual membership pricing (~30% savings vs. monthly) introduced with VIVI Cap Smart. Distribution combines direct-to-consumer e-commerce (tempramed.com with HSA/FSA support), major US retail and pharmacy channels (CVS, Walmart, Walgreens, Amazon, McKesson, Humana, US Department of Veteran Affairs), large healthcare systems in Israel (Super-Pharm, Maccabi Healthcare Services covering 2.8 million insured members), and seven international distribution agreements covering Turkey, Benelux, South Korea, Panama, Saudi Arabia, and Brazil. Go-to-market also includes a physician engagement platform (FrontrowMD with 275+ recommending clinicians) and a strategic media partnership with Dr. Phil's Envoy Media providing access to ~19M monthly viewers.

The company operates as a publicly traded entity on the Canadian Securities Exchange under the symbol VIVI (IPO October 2025) and Frankfurt Stock Exchange (November 2025), with primary entity TempraMed Ltd. (Israel) and US operations headquartered in Sammamish, Washington, plus a Texas distribution warehouse and a Florida manufacturing facility opened in December 2025 with ~1M units/year capacity. Leadership includes Founder/CEO Ron Nagar (serial medical device entrepreneur and former InsuLine Medical and Glucon co-founder), Co-Founder/COO Elina Nagar, Executive Chairman Ilan Cohen, CFO Gabi Kabazo, and CFO Israel Shay Levin, supported by a Scientific Advisory Board featuring diabetes research luminaries including Prof. Dr. Lutz Heinemann. Approximately 100,000+ units have been sold to date with a ~30% repeat purchase rate, against a stated addressable market of 160 million patients and $30 billion in global opportunity; 2024 revenue was US$2.2M with management projecting ~US$15M for 2026.

TempraMed firmographics

Firmographics
Name
TempraMed
Legal name
TempraMed Inc.
Website
https://tempramed.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
TempraMed designs and sells FDA/CE-registered VIVI thermal-protection cases for insulin and GLP-1 pens, epinephrine auto-injectors, vials, and biologics, using patented space-grade insulation and Phase Change Material technology for patients managing diabetes, severe allergies, and specialty medication regimens globally.
Ownership category
akta.pro rank

TempraMed industry classification

Industry
Product category
Temperature-Controlled Medical Storage Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYCRADAMAK
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Insulin pen protection
  • Temperature-controlled medication storage
  • Cold chain medical devices
  • GLP-1 pen cases
  • EpiPen temperature shield

Where TempraMed is headquartered

Location

Headquarters

HQ city
Sammamish
HQ country
United States
HQ region
North America

Offices4 records

Markets served

TempraMed business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

  1. Hardware Sales - VIVI Cap: One-time sale of VIVI Cap thermal insulin pen protection device; reusable for years, priced at $168/unit MSRP for B2B/pharmacy
  2. Hardware Sales - VIVI Epi: One-time sale of VIVI Epi EpiPen temperature shield for epinephrine auto-injectors
  3. Hardware Sales - VIVI Med: One-time sale of VIVI Med medication temperature protection case for vials and injectable medications including biologics and GLP-1s
  4. Hardware + Subscription - VIVI Cap Smart: Connected device combining thermal protection with digital tracking; introduces subscription-based revenue model alongside hardware sales for app features and data reports
  5. Recurring Revenue from Repeat Purchases: ~30% of customers make repeat purchases; loyalty program with points-based rewards

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goB2B Pharmacy Starter Pack
SubscriptionAnnualVIVI Cap Smart Subscription
Unit PricingPay-as-you-goConsumer Direct - Multi-Unit Bundle

Go-to-market motion5 records

Distribution channels11 records

Marketing channels8 records

TempraMed product offering

Product offering

Core offering

TempraMed designs, manufactures, and sells the VIVI line of medical-device carrying cases that passively maintain injectable medications within their safe temperature range (36–86°F) using patented space-grade insulation and self-regenerating Phase Change Material. The portfolio includes VIVI Cap and VIVI Cap Smart (insulin/GLP-1 pen cases), VIVI Epi (epinephrine auto-injector shield), and VIVI Med (vial and biologic case), with the connected VIVI Cap Smart adding Bluetooth injection tracking via a mobile app.

Product overview

TempraMed offers a portfolio of temperature-regulated medication storage products under the VIVI brand. The core offerings include VIVI Cap (insulin pen protection), VIVI Cap Smart (digital version with tracking), VIVI Epi (EpiPen protection), and VIVI Med (vial/biologic protection). The products use patented space-grade thermal insulation technology with phase change material for passive temperature control. VIVI Cap Smart adds digital health features including Bluetooth connectivity, injection tracking, and mobile app integration. Upcoming products include VIVI Box (multi-medication platform) and VIVI Cool 8C (drug storage). All products are FDA and CE registered, manufactured in the USA, and designed for the 'last mile' of medication temperature control from pharmacy to patient use.

Differentiator

Problem solved

Functional benefit

Brands

  • VIVI Cap Smart: Digitally connected temperature protection device for insulin and GLP-1 pens with injection tracking and mobile app connectivity
  • VIVI Cap
  • VIVI Epi
  • VIVI Med
  • VIVI Box
  • VIVI Cool 8C

Products and services

  • VIVI Cap Thermal insulin pen carrying case that protects insulin and GLP-1 pens from extreme temperatures using patented space-grade insulation and phase change material; maintenance-free, no batteries, works 24/7/365.
  • VIVI Cap Smart Advanced digital version of VIVI Cap combining space-grade thermal protection with injection-time tracking, Bluetooth connectivity, and a mobile application for dose logging, reminders, and shareable PDF/CSV health-provider reports.
  • VIVI Epi EpiPen temperature shield that protects epinephrine auto-injectors from extreme temperatures and light to ensure efficacy during anaphylaxis; FDA- and CE-registered, maintenance-free.
  • VIVI Med Temperature protection case for vials and injectable medications including biologics, GLP-1s, Humira, and blood glucose test strips; holds up to 2 vials and is reusable for years.
  • VIVI Box Upcoming multi-medication storage platform with thermal insulation and smart-monitoring architecture for continuous temperature protection, portable travel functionality, and cloud-based content tracking across Brazil, China, and other markets.

Quantifiable outcome

  • 86% time-in-range vs 82% without thermal protection (clinical study in Greece)
  • +4 more outcomes

Companies that use TempraMed

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles3 records

TempraMed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

TempraMed partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered major, core, flagship and minor.

  • Rawafed Health International CompanymajorChannel Partner/ Reseller/ Distributor · 26 June 2026Non-binding LOI for 5-year exclusive distribution arrangement in Saudi Arabia with minimum purchase orders of approximately US$3.1 million. Exclusivity contingent upon Saudi FDA regulatory approval and first commercial order of at least US$170,000. Initial product coverage is VIVI Cap targeting Saudi Arabia's 5.34 million adults with diabetes.
  • TEM Consulting International S.A.coreChannel Partner/ Reseller/ Distributor · 30 March 2026Non-binding LOI for distribution of VIVI temperature-regulated medication storage products across Panama. Definitive agreement expected within 90 days. Partnership targets Panama's growing diabetes and obesity markets with initial focus on urban, higher-income private-pay patients.
  • FrontrowMDmajorGTM or Marketing Partner · 26 February 2026Physician engagement platform partnership launched December 2025 where over 275 physicians across the United States recommend VIVI Cap to patients. Positions product within clinical workflow to drive patient adoption beyond traditional pharmacy channels.
  • Super-PharmmajorChannel Partner/ Reseller/ Distributor · 10 February 2026National rollout of TempraMed's temperature-protection medication products across Super-Pharm, Israel's largest pharmacy chain. Gives TempraMed access to millions of consumers through one of Israel's most trusted healthcare platforms. Products available across Super-Pharm's nationwide locations including VIVI Cap and VIVI Epi.
  • Maccabi Healthcare ServicesmajorChannel Partner/ Reseller/ Distributor · 6 February 2026National brick-and-mortar and online pharmacy rollout through Maccabi Healthcare Services, Israel's second-largest HMO serving over 2.8 million insured members. First in-store and online sales milestone demonstrating scale execution within large healthcare system.
  • Dr. Phil's Envoy MediaflagshipGTM or Marketing Partner · 2 February 2026Strategic media partnership securing exclusive title sponsorship of 44-minute television special on prescription medication safety airing May 2026. Provides access to approximately 19 million monthly viewers across broadcast TV, podcasts, YouTube, and social media platforms. TempraMed receives full content usage rights for digital acquisition, enterprise sales, and international expansion.
  • Mavens Co. LtdcoreChannel Partner/ Reseller/ Distributor · 2 January 2026Expanded distribution partnership with Mavericks Co. Ltd (Mavens) in South Korea supporting growth across Asia. Partnership strengthens TempraMed's footprint in South Korea's healthcare ecosystem targeting pharmacies, hospitals, and clinics. South Korean diabetes medications sector valued at nearly US$1 billion.
  • Professor Dr. Lutz HeinemannminorStrategic or Co-development Partner · 10 December 2025Appointment to Scientific Advisory Board. Renowned diabetes researcher providing expertise in diabetes and medication stability science to support TempraMed's thermal-stability technology expansion.
  • Salomo ExecutivecoreChannel Partner/ Reseller/ Distributor · 5 December 2025Distribution partnership expanding into Western Europe covering Benelux region (Netherlands, Belgium, and Luxembourg). Aims to increase access to TempraMed's temperature-sensitive medication storage products amid rising diabetes prevalence.
  • Dolfin SağlıkcoreChannel Partner/ Reseller/ Distributor · 2 December 2025Exclusive distribution agreement to market and sell VIVI line of medication temperature-stabilizing products in Turkey. Capitalizes on Turkey's high diabetes prevalence where about 10 million people have diabetes.
  • Guri A.A.O.majorChannel Partner/ Reseller/ Distributor · 26 November 2025Exclusive distribution agreement with leading consumer health distributor in Israel. Supports TempraMed's shift from online direct-to-consumer sales towards large retail pharmacy networks and medical payers globally.
  • bullVestor Medien GmbHminorGTM or Marketing Partner · 18 November 2025Marketing services agreement associated with Frankfurt Stock Exchange listing. Involves fee of approximately €130,000 for investor awareness services.
  • Beyond Type 1minorGTM or Marketing Partner · 27 October 2025In-kind partnership supporting 55 runners, many living with diabetes, at the 2025 TCS New York City Marathon. Provides temperature-protective solutions for runners' medications during the race.

Scale indicators10 records

Recent moves10 records

Expansion highlights7 records

TempraMed competitors and assessment

Company assessment

Direct peers

  • Frio UK: Frio UK makes evaporative cooling wallets and pouches specifically designed to keep insulin and other temperature-sensitive medications cool without refrigeration. They are a direct competitor to TempraMed's VIVI Cap, addressing the same 'last mile' cold-chain problem for insulin users via a different cooling mechanism (evaporation vs. PCM).
  • 4AllFamily: 4AllFamily produces insulated medication travel cases and cooling pouches for insulin, GLP-1 medications, and biologics, directly overlapping with TempraMed's VIVI Cap and VIVI Med products. They compete for the same insulin/GLP-1 patient demographic with a similar DTC e-commerce model.
  • Medicool: Medicool manufactures insulin protector cases and cooling wallets for diabetes patients, including products designed for portable temperature control of insulin pens and vials. They are a legacy direct competitor in the insulin storage category that TempraMed is disrupting with newer PCM-based technology.

Broad incumbents

  • Becton Dickinson (BD): Becton Dickinson is a global medical technology giant with a broad portfolio of drug delivery devices (including insulin pens, auto-injectors, and prefilled syringes) and medication management accessories. While not focused on temperature protection specifically, BD has the scale and distribution to enter TempraMed's niche.
  • Medtronic: Global medical device leader with diabetes (insulin pumps, CGM) and broader medical device portfolios. Susan Alpert, former Senior VP Global Regulatory Affairs at Medtronic, sits on TempraMed's advisory board, highlighting the potential incumbent threat in medication management devices.

Emerging players

  • Apex Medical Corporation: Apex Medical develops medical device accessories for chronic disease management, with overlap in medication storage and portability products. While broader in scope, they are an emerging player in adjacent patient-focused medical device categories.
  • Ypsomed: Swiss-based manufacturer of insulin pens, auto-injectors, and smart injection devices. Their mySmartPilot and YpsoMate platforms overlap with TempraMed's VIVI Cap Smart in addressing smart injection tracking for diabetes patients, though Ypsomed focuses on delivery rather than temperature protection.

Others

  • Novo Nordisk: The world's largest insulin manufacturer and major GLP-1 producer (Ozempic, Wegovy). While not a direct competitor, Novo Nordisk could choose to bundle or co-promote temperature protection accessories with their injectable medications, representing both a potential partner and a threat to TempraMed's market position.
  • Eli Lilly: Major GLP-1 manufacturer (Mounjaro, Zepbound) and insulin producer. As with Novo Nordisk, Lilly represents both a potential partner opportunity and a competitive threat, as they could develop proprietary or branded temperature protection solutions for their injectable portfolio.
  • Insulet: Insulet manufactures the Omnipod insulin patch pump, a leading insulin delivery system. While not directly competing in temperature protection, Insulet targets the same diabetes patient demographic and represents an adjacent diabetes management technology competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

TempraMed compliance and trust

Trust signal

Compliance3 records

TempraMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TempraMed leadership team

Management profile

Number of profiles

Profiles20 records

TempraMed subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

TempraMed funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TempraMed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TempraMed

What does TempraMed do?

TempraMed designs, manufactures, and sells the VIVI line of medical-device carrying cases that passively maintain injectable medications within their safe temperature range (36–86°F) using patented space-grade insulation and self-regenerating Phase Change Material. The portfolio includes VIVI Cap and VIVI Cap Smart (insulin/GLP-1 pen cases), VIVI Epi (epinephrine auto-injector shield), and VIVI Med (vial and biologic case), with the connected VIVI Cap Smart adding Bluetooth injection tracking via a mobile app.

Is TempraMed a public or private company?

TempraMed is a public company. It is classified as public and is currently operating.

When was TempraMed founded?

TempraMed was founded in 2012. It employs 1 to 10 people.

Where is TempraMed based?

TempraMed is headquartered in Sammamish, United States, in the North America region.

How does TempraMed make money?

Five revenue lines are on record. Hardware Sales - VIVI Cap is the primary driver. The others are hardware Sales - VIVI Epi, hardware Sales - VIVI Med, hardware + Subscription - VIVI Cap Smart and recurring Revenue from Repeat Purchases.

Who are TempraMed's main competitors?

Direct peers on record are Frio UK, 4AllFamily and Medicool. Broad incumbents are Becton Dickinson (BD) and Medtronic. Emerging players are Apex Medical Corporation and Ypsomed. Others are Novo Nordisk, Eli Lilly and Insulet.

Does TempraMed have an API?

No public API is recorded for TempraMed.

What industry is TempraMed in?

TempraMed's product category is Temperature-Controlled Medical Storage Devices. Its primary akta.pro industry code is CRADAMAK, Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.de500.000 USD Mindestabnahme: Diese Small-Cap-Aktie könnte nach dieser News vor einer spannenden Neubewertung stehen!TempraMed Technologies signed an exclusive Kuwait distribution deal with 36-month minimum orders of about $500,000, covering its full product line. The company reported record July and August revenue of $522,000 and $403,000, surpassing 2025's full-year total. It also received a Mexican patent for VIVI Box and plans a US listing.TradingViewTempraMed Technologies Ltd. (VIVI) Signs Exclusive Kuwait Deal Worth Approx. $500K Over 3 YearsTempraMed signed an exclusive distribution agreement with OGM in Kuwait for its VIVI products, covering Cap/Smart, Med, and Epi. The deal has a 36-month term with approximately $500K in potential minimum purchases, subject to regulatory clearances and commercialization.FinanzNachrichten.deMexiko gibt grünes Licht: Nächster Paukenschlag! Patent bis 2039: Ist das der nächste große Wachstumstreiber für diese Small-Cap-Aktie?TempraMed Technologies received a Mexican patent for VIVI Box, its multi-medication cooler, with protection until 2039. The company reported record July and August revenue of $522,000 and $403,000, respectively, and expects a stronger third quarter. It also announced expansion into seven Latin American countries and a distribution deal with CenterWell Pharmacy.NewsfileTempraMed Granted Mexican Patent for Newest Product, VIVI BoxTempraMed Technologies granted a Mexican patent for its VIVI Box multi-medication storage platform, covering thermal-insulation and smart-monitoring features. The patent term extends through October 24, 2039, and the box will add to the company's existing product portfolio.Stock TitanTempraMed's VIVI Box patent granted in MexicoTempraMed Technologies announced that its Mexican patent application for the VIVI Box multi-medication storage platform was granted by the Mexican Patent Office. The patent covers thermal-insulation and smart-monitoring features and extends through October 24, 2039. The company plans to launch the product, adding to its existing portfolio of four products.AktienTempraMed Granted Mexican Patent for Newest Product, VIVI BoxTempraMed Technologies Ltd. announced that its Mexican patent application for the VIVI Box multi-medication storage platform was granted by the Mexican Patent Office. The patent covers thermal-insulation and smart-monitoring features, with a term extending through October 24, 2039. The grant supports the company's commercialization strategy and engagement with appliance manufacturers.BioSpaceTempraMed Technologies Ltd. Announces Closing of Private PlacementTempraMed Technologies closed a non-brokered private placement of convertible debentures and units, raising $1,177,940 in gross proceeds. The company will use the funds for inventory, product development, and scaling its sales and marketing division globally.Investing.comTempraMed closes $1.18M financing with debentures and unitsTempraMed Technologies completed a non-brokered private placement raising $1,177,940, consisting of $600,000 in debentures and 1,155,880 units. The debentures carry 10% interest and convert at $0.50 per share, with proceeds funding inventory, product development, and working capital.Investing.comTempraMed closes $1.18M financing with debentures and unitsTempraMed Technologies completed a non-brokered private placement raising $1,177,940, consisting of $600,000 in debentures and 1,155,880 units. The debentures carry 10% interest and convert at $0.50 per share, with proceeds funding inventory, product development, and working capital.NewsfileTempraMed Technologies Ltd. Announces Closing of Private PlacementTempraMed Technologies Ltd. closed a non-brokered private placement of unsecured convertible debentures and units, raising $1,177,940 in gross proceeds. The offering included $600,000 of debentures and 1,155,880 units, with proceeds to fund inventory, product development, and global sales and marketing.